Selected article for: "antiviral response and DNA virus"

Author: Chiang, Cindy; Dvorkin, Steve; Chiang, Jessica J.; Potter, Rachel B.; Gack, Michaela U.
Title: The Small t Antigen of JC Virus Antagonizes RIG-I-Mediated Innate Immunity by Inhibiting TRIM25’s RNA Binding Ability
  • Cord-id: k6t2khtw
  • Document date: 2021_4_13
  • ID: k6t2khtw
    Snippet: JC polyomavirus (JCV), a DNA virus that leads to persistent infection in humans, is the causative agent of progressive multifocal leukoencephalopathy, a lethal brain disease that affects immunocompromised individuals. Almost nothing is currently known about how JCV infection is controlled by the innate immune response and, further, whether JCV has evolved mechanisms to antagonize antiviral immunity. Here, we show that the innate immune sensors retinoic acid-inducible gene I (RIG-I) and cGMP-AMP
    Document: JC polyomavirus (JCV), a DNA virus that leads to persistent infection in humans, is the causative agent of progressive multifocal leukoencephalopathy, a lethal brain disease that affects immunocompromised individuals. Almost nothing is currently known about how JCV infection is controlled by the innate immune response and, further, whether JCV has evolved mechanisms to antagonize antiviral immunity. Here, we show that the innate immune sensors retinoic acid-inducible gene I (RIG-I) and cGMP-AMP synthase (cGAS) control JCV replication in human astrocytes. We further identify that the small t antigen (tAg) of JCV functions as an interferon (IFN) antagonist by suppressing RIG-I-mediated signal transduction. JCV tAg interacts with the E3 ubiquitin ligase TRIM25, thereby preventing its ability to bind RNA and to induce the K63-linked ubiquitination of RIG-I, which is known to facilitate RIG-I-mediated cytokine responses. Antagonism of RIG-I K63-linked ubiquitination and antiviral signaling is also conserved in the tAg of the related polyomavirus BK virus (BKV). These findings highlight how JCV and BKV manipulate a key innate surveillance pathway, which may stimulate research into designing novel therapies.

    Search related documents:
    Co phrase search for related documents
    • active replication and luciferase activity: 1
    • acute sars cov respiratory syndrome coronavirus and adaptor protein: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and additional control: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and long noncoding: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and low protein expression: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and luciferase activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • additional control and luciferase activity: 1
    • lncrna long noncoding rna and long noncoding: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • lncrna long noncoding rna and long noncoding rna: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • lncrna long noncoding rna and luciferase activity: 1
    • long noncoding and luciferase activity: 1
    • long noncoding rna and luciferase activity: 1
    • low protein expression and luciferase activity: 1